Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Prostate Cancer
New Compounds Hold Promise for Prostate Cancer
Prostate Cancer
,
Solid Tumors
September 2010, Vol 1, No 4
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease (CRPC). Docetaxel, the standard of care for these patients, provides a modest prolongation of survival, but there is an urgent need for novel treatment strategies.
Read Article
Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer
FDA Approvals, News & Updates
,
Prostate Cancer
2019 Fourth Annual Oncology Guide to New FDA Approvals
Prostate cancer is the third most common type of cancer in the United States, after breast cancer and lung cancer. In 2018 alone, 164,690 individuals were diagnosed with prostate cancer, accounting for nearly 10% of all new cancer cases, and 29,430 deaths were attributed to the disease. Prostate cancer is most frequently diagnosed in men aged 65 to 74 years (median age, 66 years). More than 98% of patients with prostate cancer survive ≥5 years; however, the 5-year survival rate drops to 30% for patients with metastatic disease.
Read Article
Darolutamide, New Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in High-Risk Prostate Cancer
By
Phoebe Starr
Prostate Cancer
April 2019, Vol 10, No 2
San Francisco, CA—Darolutamide, an investigational androgen receptor inhibitor, significantly improved metastasis-free survival in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC) compared with placebo in a large phase 3 clinical trial.
Read Article
Expert Panel Tackles Merits of End Points in Castrate-Resistant Prostate Cancer: Impact on Treatment and Coverage Decisions
By
Wayne Kuznar
AVBCC Special Feature
,
Prostate Cancer
Web Exclusives
Nearly 12% of American men will be diagnosed with prostate cancer at some point during their lives. Prostate cancer may remain indolent, but it often requires treatment, as evidenced by the more than 26,000 deaths attributable to this disease annually. Although the 5-year survival is high for men with localized prostate cancer, this drops to 29% in men with metastatic prostate cancer. Even with treatment, prostate cancer progresses in more than 33% of men. The median time to metastatic disease is approximately 8 to 10 years after the detection of biochemical recurrence.
Read Article
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
By
Wayne Kuznar
Prostate Cancer
,
Solid Tumors
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—The results from 2 studies should advance the use of abiraterone acetate (Zytiga) to the frontline treatment of patients with hormone-sensitive advanced prostate cancer, effectively replacing chemotherapy, said several experts at the 2017 ASCO annual meeting.
Read Article
Death Rates Unaffected by Treatment Choice for Patients with Localized Prostate Cancer
By
Alice Goodman
Prostate Cancer
,
Solid Tumors
October 2016, Vol 7, No 9
Read Article
Role of Cancer Cell Count in Assessing Therapy Efficacy in Prostate Cancer
By
Sophie Granger
Prostate Cancer
,
Solid Tumors
October 2016, Vol 7, No 9
Read Article
Changes in Patient-Reported Outcomes Linked to Better Survival in Metastatic Prostate Cancer
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Patient-reported outcomes had significant associations with survival in metastatic castration-resistant prostate cancer (mCRPC), suggesting potential implications for clinical management, reported Tomasz M. Beer, MD, Oregon Health & Science University, Knight Cancer Institute, Portland, and colleagues, at the 2016 International Society for Pharmacoeconomics and Outcomes Research annual meeting.
Read Article
Rise in Metastatic Prostate Cancer Has Screening, Treatment Implications
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
The incidence of metastatic prostate cancer increased by >70% from 2004 to 2013, including >90% in the age-group most likely to benefit from definitive treatment, according to a new analysis of a national database (Weiner AB, et al.
Prostate Cancer Prostatic Dis
. 2016 Jul 19. Epub ahead of print).
Read Article
Shorter Hypofractionated Therapy New Standard for Prostate Cancer
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Men with intermediate-risk prostate cancer can safely undergo radiation administered in larger fractions for 4 weeks (moderate hypofractionation) as an alternative to conventional radiation administered for 8 weeks, according to the results of a randomized, controlled, noninferiority clinical trial presented at ASCO 2016.
Read Article
Page 3 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma